Dyno Therapeutics applys AI and quantitative in vivo experiments to expand the range of diseases treatable with gene therapies.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/06/2021 | Series A | $100MM | $xx.xx | $53.93B | Andreessen Horowitz, Casdin Capital, Gv, Lux Capital, Obvious Ventures | |
Price per Share
$xx.xx
Shares Outstanding
2,238,968
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Casdin Capital, Gv, Lux Capital, Obvious Ventures
|
||||||
05/11/2020 | Series Seed-N | $2MM | $xx.xx | $5.92B | Crv, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
270,686
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Crv, Polaris Partners
|
||||||
05/11/2020 | Series Seed | $9MM | $xx.xx | $5.92B | Crv, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
2,131,651
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Crv, Polaris Partners
|